News $74bn BMS/Celgene merger finally cleared by competition regu... Bristol-Myers Squibb and Celgene’s merger looks set to close tomorrow after US competition regulators finally gave the $74 billion deal the go-ahead.
News BMS' Opdivo misses target in aggressive brain cancer trial It’s never good news when a drug firm posts an “update” about a phase 3 trial, and Bristol-Myers Squibb’s PR team have had to issue news of another trial disappointment from the misfiring c
News Biogen, Denali pull Parkinson's drug after failed trial Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle in a phase 2b trial.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
